McNeil Consumer Healthcarecan increase its OTC drug manufacturing capacity as FDA signs off on remediation of the Johnson & Johnson subsidiary’s headquarters facility that was closed under a consent decree.
In a statement to “The Tan Sheet,” J&J/McNeil said FDA officials on Aug. 21 notified the firm that the Fort...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?